Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) shares fell 2.7% during trading on Tuesday . The company traded as low as $3.45 and last traded at $3.54, with a volume of 53,475 shares trading hands. The stock had previously closed at $3.64.

A number of brokerages recently commented on CATB. Zacks Investment Research downgraded Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a report on Monday, July 18th. Wedbush reissued an “outperform” rating and issued a $17.00 price target (down previously from $27.00) on shares of Catabasis Pharmaceuticls in a report on Tuesday, June 7th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Saturday, May 14th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $19.05.

The company has a 50-day moving average price of $3.97 and a 200-day moving average price of $5.08. The stock’s market cap is $53.50 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.03. On average, analysts expect that Catabasis Pharmaceuticls Inc. will post ($2.52) earnings per share for the current year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.